LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis

    Roy Fleischmann / Yoshiya Tanaka / Paul Emery / Vivian P Bykerk / Sean E Connolly / Chun Wu / Robert Wong / Jinqi Liu / Peter Schafer / Yanhua Hu / Anne-Christine Bay-Jensen / Signe Holm Nielsen / Thomas WJ Huizinga

    RMD Open, Vol 8, Iss

    2022  Volume 2

    Abstract: Objective To investigate correlations between biomarkers of bone remodelling and extracellular matrix turnover with baseline disease activity and treatment response in patients with early rheumatoid arthritis (RA).Methods Assessing Very Early Rheumatoid ... ...

    Abstract Objective To investigate correlations between biomarkers of bone remodelling and extracellular matrix turnover with baseline disease activity and treatment response in patients with early rheumatoid arthritis (RA).Methods Assessing Very Early Rheumatoid arthritis Treatment-2 (AVERT-2; NCT02504268) included disease-modifying antirheumatic drug-naive, anti-citrullinated protein antibody (ACPA)-positive patients randomised to weekly subcutaneous abatacept+methotrexate (MTX) or abatacept placebo+MTX for 56 weeks. This post hoc exploratory subanalysis assessed the association between baseline disease activity and eight biomarkers (Spearman’s correlation coefficient), and whether baseline biomarkers (continuous or categorical variables) could predict treatment response at weeks 24 and 52 (logistic regression).Results Patient characteristics were similar between overall (n=752) and biomarker subgroup (n=535) populations and across treatments. At baseline, neoepitopes of matrix metalloproteinase-mediated degradation products of types III and IV collagen and of C reactive protein (CRP) showed the greatest correlations with disease activity; cross-linked carboxy-terminal telopeptide of type I collagen (CTX-I) showed weak correlation. Only CTX-I predicted treatment response; baseline CTX-I levels were significantly associated with achieving Simplified Disease Activity Index remission and Disease Activity Score in 28 joints (DAS28 (CRP)) <2.6 (weeks 24 and 52), and American College of Rheumatology 70 response (week 52), in patients treated with abatacept+MTX but not abatacept placebo+MTX. CTX-I predicted significant differential response between arms for DAS28 (CRP) <2.6 (week 24). Treatment differences were greater for abatacept+MTX in patients with medium/high versus low baseline CTX-I.Conclusion In MTX-naive, ACPA-positive patients with early RA, baseline CTX-I predicted treatment response to abatacept+MTX but not abatacept placebo+MTX.
    Keywords Medicine ; R
    Subject code 610 ; 616
    Language English
    Publishing date 2022-11-01T00:00:00Z
    Publisher BMJ Publishing Group
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  2. Article ; Online: PROMIS Fatigue short forms are reliable and valid in adults with rheumatoid arthritis

    Clifton O. Bingham III / Anna Kristina Gutierrez / Alessandra Butanis / Vivian P. Bykerk / Jeffrey R. Curtis / Amye Leong / Anne Lyddiatt / W. Benjamin Nowell / Ana Maria Orbai / Susan J. Bartlett

    Journal of Patient-Reported Outcomes, Vol 3, Iss 1, Pp 1-

    2019  Volume 9

    Abstract: Abstract Background Fatigue is prevalent and impactful in rheumatoid arthritis (RA). There is no standardized measure for its assessment nor data concerning the performance of PROMIS-Fatigue short forms (SFs) in people with RA. We evaluated the construct ...

    Abstract Abstract Background Fatigue is prevalent and impactful in rheumatoid arthritis (RA). There is no standardized measure for its assessment nor data concerning the performance of PROMIS-Fatigue short forms (SFs) in people with RA. We evaluated the construct validity of 4-, 7-, and 8-item PROMIS-Fatigue SFs in RA patients across the range of disease activity. Methods Adult RA patients were recruited from an online patient community and an observational cohort from three academic medical centers. Measures included PROMIS-Fatigue SFs, other PROMIS measures, and other patient reported outcomes including RAND-36 Vitality, Fatigue NRS, and patient global assessment of disease activity. Other measures from the observational cohort included 28-joint swollen and tender joints, physician global assessment, and the composite RA clinical disease activity index (CDAI). Results Two-hundred online participants and 348 participants from the observational cohort were included. PROMIS Fatigue SF scores spanned the measurement continuum and correlated highly with each other (r’s ≥ 0.91) and other fatigue measures (r’s ≥ 0.85). PROMIS-Fatigue SF scores were highly and inversely associated with Physical Function and Participation (r’s − 0.77 to − 0.78), and moderately-highly and positively correlated with pain, sleep disturbance, anxiety, and depression (r’s 0.60 to 0.75). PROMIS-Fatigue SF scores showed dose-response relationships across fatigue severity descriptors and CDAI categories. Conclusions These results provide robust evidence supporting the construct validity of the 4, 7, and 8-item PROMIS-Fatigue SFs. They capture fatigue across the spectrum of RA disease activity in diverse groups of individuals and should be considered for use as patient-centered assessments of disease control and treatment efficacy.
    Keywords Patient reported outcomes ; Fatigue ; Rheumatoid arthritis ; Validation ; PROMIS ; Public aspects of medicine ; RA1-1270
    Subject code 669
    Language English
    Publishing date 2019-02-01T00:00:00Z
    Publisher SpringerOpen
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article ; Online: Single-cell RNA-seq of rheumatoid arthritis synovial tissue using low-cost microfluidic instrumentation

    William Stephenson / Laura T. Donlin / Andrew Butler / Cristina Rozo / Bernadette Bracken / Ali Rashidfarrokhi / Susan M. Goodman / Lionel B. Ivashkiv / Vivian P. Bykerk / Dana E. Orange / Robert B. Darnell / Harold P. Swerdlow / Rahul Satija

    Nature Communications, Vol 9, Iss 1, Pp 1-

    2018  Volume 10

    Abstract: Droplet-based single-cell RNA-seq is a powerful tool for cellular heterogeneity profiling in disease but is limited by instrumentation required. Here the authors develop a 3D printed microfluidic platform for massive parallel sequencing of rheumatoid ... ...

    Abstract Droplet-based single-cell RNA-seq is a powerful tool for cellular heterogeneity profiling in disease but is limited by instrumentation required. Here the authors develop a 3D printed microfluidic platform for massive parallel sequencing of rheumatoid arthritis tissues.
    Keywords Science ; Q
    Language English
    Publishing date 2018-02-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article ; Online: Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH).

    Cheryl Barnabe / Ye Sun / Gilles Boire / Carol A Hitchon / Boulos Haraoui / J Carter Thorne / Diane Tin / Désirée van der Heijde / Jeffrey R Curtis / Shahin Jamal / Janet E Pope / Edward C Keystone / Susan Bartlett / Vivian P Bykerk / CATCH Investigators

    PLoS ONE, Vol 10, Iss 8, p e

    2015  Volume 0135327

    Abstract: Our objective was to identify distinct trajectories of disease activity state (DAS) and assess variation in radiographic progression, function and quality of life over the first two years of early rheumatoid arthritis (ERA). The CATCH (Canadian early ... ...

    Abstract Our objective was to identify distinct trajectories of disease activity state (DAS) and assess variation in radiographic progression, function and quality of life over the first two years of early rheumatoid arthritis (ERA). The CATCH (Canadian early ArThritis CoHort) is a prospective study recruiting ERA patients from academic and community rheumatology clinics in Canada. Sequential DAS28 scores were used to identify five mutually exclusive groups in the cohort (n = 1,586) using growth-based trajectory modeling. Distinguishing baseline sociodemographic and disease variables, treatment required, and differences in radiographic progression and quality of life measures over two years were assessed. The trajectory groups are characterized as: Group 1 (20%) initial high DAS improving rapidly to remission (REM); Group 2 (21%) initial moderate DAS improving rapidly to REM; Group 3 (30%) initial moderate DAS improving gradually to low DAS; Group 4 (19%) initial high DAS improving continuously to low DAS; and Group 5 (10%) initial high DAS improving gradually only to moderate DAS. Groups differed significantly in age, sex, race, education, employment, income and presence of comorbidities. Group 5 had persistent steroid requirements and the highest biologic therapy use. Group 2 had lower odds (OR 0.22, 95%CI 0.09 to 0.58) and Group 4 higher odds (OR 1.94, 95%CI 0.90 to 4.20) of radiographic progression compared to Group 1. Group 1 had the best improvement in physical function (Health Assessment Questionnaire 1.08 (SD 0.68) units), Physical Component Score (16.4 (SD 10.2) units), Mental Component Score (9.7 (SD 12.5) units) and fatigue (4.1 (SD 3.3) units). In conclusion, distinct disease activity state trajectories explain variable outcomes in ERA. Early prediction of disease course to tailor therapy and addressing social determinants of health could optimize outcomes.
    Keywords Medicine ; R ; Science ; Q
    Subject code 796
    Language English
    Publishing date 2015-01-01T00:00:00Z
    Publisher Public Library of Science (PLoS)
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article ; Online: Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis

    Fumitaka Mizoguchi / Kamil Slowikowski / Kevin Wei / Jennifer L. Marshall / Deepak A. Rao / Sook Kyung Chang / Hung N. Nguyen / Erika H. Noss / Jason D. Turner / Brandon E. Earp / Philip E. Blazar / John Wright / Barry P. Simmons / Laura T. Donlin / George D. Kalliolias / Susan M. Goodman / Vivian P. Bykerk / Lionel B. Ivashkiv / James A. Lederer /
    Nir Hacohen / Peter A. Nigrovic / Andrew Filer / Christopher D. Buckley / Soumya Raychaudhuri / Michael B. Brenner

    Nature Communications, Vol 9, Iss 1, Pp 1-

    2018  Volume 11

    Abstract: Synovial fibroblasts are thought to be central mediators of joint destruction in rheumatoid arthritis (RA). Here the authors use single-cell transcriptomics and flow cytometry to identify synovial fibroblast subsets that are expanded and display distinct ...

    Abstract Synovial fibroblasts are thought to be central mediators of joint destruction in rheumatoid arthritis (RA). Here the authors use single-cell transcriptomics and flow cytometry to identify synovial fibroblast subsets that are expanded and display distinct tissue distribution and function in patients with RA.
    Keywords Science ; Q
    Language English
    Publishing date 2018-02-01T00:00:00Z
    Publisher Nature Publishing Group
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  6. Article ; Online: Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis

    Fumitaka Mizoguchi / Kamil Slowikowski / Kevin Wei / Jennifer L. Marshall / Deepak A. Rao / Sook Kyung Chang / Hung N. Nguyen / Erika H. Noss / Jason D. Turner / Brandon E. Earp / Philip E. Blazar / John Wright / Barry P. Simmons / Laura T. Donlin / George D. Kalliolias / Susan M. Goodman / Vivian P. Bykerk / Lionel B. Ivashkiv / James A. Lederer /
    Nir Hacohen / Peter A. Nigrovic / Andrew Filer / Christopher D. Buckley / Soumya Raychaudhuri / Michael B. Brenner

    Nature Communications, Vol 9, Iss 1, Pp 1-

    2018  Volume 11

    Abstract: Synovial fibroblasts are thought to be central mediators of joint destruction in rheumatoid arthritis (RA). Here the authors use single-cell transcriptomics and flow cytometry to identify synovial fibroblast subsets that are expanded and display distinct ...

    Abstract Synovial fibroblasts are thought to be central mediators of joint destruction in rheumatoid arthritis (RA). Here the authors use single-cell transcriptomics and flow cytometry to identify synovial fibroblast subsets that are expanded and display distinct tissue distribution and function in patients with RA.
    Keywords Science ; Q
    Language English
    Publishing date 2018-02-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top